Warren Nighan, Jr. Sells 23,370 Shares of AngioDynamics (NASDAQ:ANGO) Stock

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

AngioDynamics Trading Up 0.1%

Shares of AngioDynamics stock opened at $14.79 on Friday. AngioDynamics, Inc. has a 12-month low of $8.36 and a 12-month high of $15.19. The company has a market cap of $611.27 million, a P/E ratio of -17.00 and a beta of 0.34. The company’s fifty day simple moving average is $12.81 and its two-hundred day simple moving average is $11.50.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts predict that AngioDynamics, Inc. will post -0.27 EPS for the current fiscal year.

Analyst Ratings Changes

ANGO has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. HC Wainwright raised their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $19.50.

Institutional Trading of AngioDynamics

Several institutional investors have recently added to or reduced their stakes in ANGO. Franklin Resources Inc. lifted its stake in AngioDynamics by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after acquiring an additional 1,076 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 1,199 shares during the last quarter. Deutsche Bank AG grew its stake in shares of AngioDynamics by 5.9% in the fourth quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after acquiring an additional 1,992 shares during the period. Kemnay Advisory Services Inc. bought a new stake in shares of AngioDynamics in the fourth quarter worth approximately $27,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of AngioDynamics by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock valued at $569,000 after purchasing an additional 2,263 shares during the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.